logo
logo

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

Oct 28, 2024•9 months ago

Contract Type

partnership

DenmarkHealthcare

Description

BioPorto A/S has entered into a global distribution partnership with Beckman Coulter, Inc. The partnership aims to distribute BioPorto's neutrophil gelatinase-associated lipocalin (NGAL) tests for use on Beckman Coulter family of DxC and AU clinical chemistry analyzers. The agreement includes distribution in Europe and potential expansion into the United States pending US FDA marketing clearance, with opportunities for further geographic expansion.

Company Information

Company

BioPorto A/S

Location

TUBORG HAVNEVEJ 15, ST

Denmark

About

BioPorto is a global in-vitro diagnostics company that provides tests and antibodies to clinicians and researchers. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. Headquartered in Hellerup, Denmark, with US headquarters outside Boston, Massachusetts, BioPorto is listed on the NASDAQ Copenhagen stock exchange. [CPH: BIOPOR]

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Related People